📊 BIOA Key Takeaways
Investment Thesis
BioAge Labs is a pre-revenue pharmaceutical company with severe cash burn, negative margins exceeding -900%, and operating cash flow of -$53.4M against only $5.9M in revenue. While the company maintains a strong cash position of $215.6M and zero debt, the current burn rate and lack of revenue traction present substantial execution risk with limited runway given the magnitude of losses.
BIOA Strengths
- Strong liquidity position with $215.6M in cash and 11.87x current ratio
- Zero long-term debt provides financial flexibility without refinancing pressure
- Early-stage biotech with substantial stockholders equity of $277.5M
- Recent insider activity (13 Form 4 filings) indicates ongoing management engagement
BIOA Risks
- Severe cash burn of $53.4M operating cash flow with only $5.9M revenue, implying ~4 years runway at current rate
- Extreme negative margins (-923.8% net margin) indicating inability to monetize operations
- Pre-revenue stage in competitive pharmaceutical sector with no clear path to profitability demonstrated
- High dilution risk from continued equity financing to fund operations and R&D
Key Metrics to Watch
- Quarterly revenue growth and path to positive gross margins
- Operating cash burn rate and monthly cash consumption trends
- Clinical trial progress and regulatory milestones for pipeline assets
- Cash runway extension timeline and upcoming financing requirements
BIOA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 11.87x current ratio provides a solid financial cushion.
BIOA Profitability Ratios
BIOA vs Healthcare Sector
How BioAge Labs, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BIOA Balance Sheet & Liquidity
BIOA 5-Year Financial Trend
5-Year Trend Summary: BioAge Labs, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-38.17 indicates the company is currently unprofitable.
BIOA Growth Metrics (YoY)
BIOA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$12.9M | $-0.56 |
| Q2 2025 | N/A | -$12.9M | $-0.60 |
| Q1 2025 | $1.5M | -$12.9M | $-0.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BIOA Capital Allocation
BIOA SEC Filings
Access official SEC EDGAR filings for BioAge Labs, Inc. (CIK: 0001709941)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 3, 2026 | 4 | xslF345X05/form4-03032026_090341.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/form4-03032026_090347.xml | View → |
| Feb 19, 2026 | 4 | xslF345X05/form4-02192026_090237.xml | View → |
| Feb 19, 2026 | 4 | xslF345X05/form4-02192026_090237.xml | View → |
| Feb 19, 2026 | 4 | xslF345X05/form4-02192026_090219.xml | View → |
❓ Frequently Asked Questions about BIOA
What is the AI rating for BIOA?
BioAge Labs, Inc. (BIOA) has an AI rating of SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIOA's key strengths?
Strong liquidity position with $215.6M in cash and 11.87x current ratio. Zero long-term debt provides financial flexibility without refinancing pressure.
What are the risks of investing in BIOA?
Severe cash burn of $53.4M operating cash flow with only $5.9M revenue, implying ~4 years runway at current rate. Extreme negative margins (-923.8% net margin) indicating inability to monetize operations.
What is BIOA's revenue and growth?
BioAge Labs, Inc. reported revenue of $5.9M.
Does BIOA pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
Where can I find BIOA SEC filings?
Official SEC filings for BioAge Labs, Inc. (CIK: 0001709941) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIOA's EPS?
BioAge Labs, Inc. has a diluted EPS of $-1.52.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.